Researchers at Moffitt Cancer Center have developed a new chemical approach that could help make targeted cancer medicines safer and more precise. The discovery gives scientists a new way to design drugs that bind more selectively to cancer-driving proteins while reducing unwanted interactions that can lead to side effects.